CF
LKFT

Centaurus Financial’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Centaurus Financial’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3
Closed – – 1128
2018
Q2 		$0 Buy
+3
New +$291 ﹤0.01% 2294

Other funds holding LKFT

Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Centaurus Financial's LKFT Position: Q3 2018 in Review

Centaurus Financial sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q3 2018, closing a stake of 3 shares.

Centaurus Financial first reported a position in LKFT in Q2 2018 and held it in 1 quarter. The position peaked at $0 in Q2 2018. 92 funds tracked by Wall St. Rank hold LKFT as of Q3 2018.

  • Centaurus Financial reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q3 2018 after selling out during the quarter.
  • Centaurus Financial sold 3 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2018.
  • Centaurus Financial first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2018 and held it in 1 quarter.
  • Centaurus Financial's Lakefront Biotherapeutics American Depositary Shares position peaked at $0 in Q2 2018.
  • 92 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.